



## Solid Biosciences to Participate at Upcoming Investor Conferences

September 29, 2022

CHARLESTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and CEO, and Carl Morris, Ph.D., Chief Scientific Officer, will participate at the following two upcoming investor conferences:

- **Jefferies Cell and Genetic Medicine Summit – New York, NY**  
Fireside chat on Friday, September 30, 2022 at 3:00 PM ET.
- **Chardan's 6th Annual Genetic Medicines Conference – New York, NY**  
Fireside chat on Tuesday, October 4, 2022 at 1:00 PM ET.

A live webcast of these presentations will be available on the Company's investor relations website, under the Events page accessible here: <https://investors.solidbio.com/news-and-events/events>. A replay will be available on the Company's website following the events.

### About Solid Biosciences

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our gene therapy candidates, SGT-001 and SGT-003. For more information, please visit [www.solidbio.com](http://www.solidbio.com).

### Investor Contacts:

Caitlin Lowie  
Solid Biosciences  
607-423-3219  
[Clowie@solidbio.com](mailto:Clowie@solidbio.com)

David Carey  
FINN Partners  
212-867-1768  
[David.Carey@finnpartners.com](mailto:David.Carey@finnpartners.com)

### Media Contact:

Erich Sandoval  
FINN Partners  
917-497-2867  
[Erich.Sandoval@finnpartners.com](mailto:Erich.Sandoval@finnpartners.com)



Source: Solid Biosciences Inc.